gip (1-42)

Peptideexperimental

Clinical trial activity

11 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Jan 31, 2008 (NCT00732602)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • gip (1-42)

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06934473N/AMay 21, 2025University of Copenhagen
NCT06194955N/AJan 4, 2023University of Copenhagen
NCT06137586N/AAug 10, 2022Novo Nordisk, University of Copenhagen
NCT03950245N/AMay 31, 2019University of Copenhagen
NCT03770910N/ADec 6, 2018Steno Diabetes Center Copenhagen, University of Copenhagen
NCT04792762N/AJun 12, 2018University of Copenhagen
NCT03526289N/ANov 8, 2017University of Copenhagen, Zealand Pharma
NCT02747472N/AApr 1, 2016University of Copenhagen
NCT01880827Phase 1Jan 1, 2013Government of Finland, Lund University, Sigrid Juselius Foundation, University of Turku
NCT00809029N/AApr 30, 2011Royal Liverpool & Broadgreen University Hospitals NHS Truts
NCT00732602N/AJan 31, 2008University of Copenhagen
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of CopenhagenAcademic/Hospital9912008
Government of FinlandGovernment1012013
Lund UniversityAcademic/Hospital1012013
Novo NordiskFor profit1012022
Royal Liverpool & Broadgreen University Hospitals NHS TrutsAcademic/Hospital1112011
Sigrid Juselius FoundationAcademic/Hospital1012013
Steno Diabetes Center CopenhagenAcademic/Hospital1012018
University of TurkuAcademic/Hospital1112013
Zealand PharmaFor profit1012017
9 organizations
Page 1 / 1